CAMBIO DE DISCURSO : ADIÓS A LA SEGUNDA LÍNEA SCLC-ES EN EEUU Y EN EU ...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE /// SI NO EXISTIERA IMFORTE ... AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN /// IMFORTE EN EU DE UN TAM DE 600 MILLONES A UN MERCADO REAL MUCHO MENOR QUE PODRÍA SER DE TAN SOLO UNOS 85 MILLONES /// 2 DE OCTUBRE DE 2028 ... ES LA FECHA PARA LA POSIBLE ENTRADA DE GENÉRICOS DE LURBINECTEDIN ...
19 octubre 2019
Eribulin . Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment .
Download PDF (3033K)
Pneumothorax has Been Reported as a Pazopanib
-Associated Adverse Event in Patients with Lung Metastases of Soft Tissue Sarcoma (STS).
However, Pneumothorax Triggered by Eribulin Treatment has Mever Been Reported.
We herein report two cases of spontaneous Pneumothorax in Patients with STS treated with Eribulin. Both Patients experienced Pneumothorax accompanied by sudden dyspnea on day 9 or 10 of Eribulin Treatment. These two cases suggest that spontaneous Pneumothorax may occur as an adverse event of Eribulin treatment in such Patients.
We should therefore be alert for the potential development of Pneumothorax during Eribulin Treatment of Patients with STS and Lung Metastases.
Suscribirse a:
Entradas (Atom)


